United States· US:64764-171_402fdd3a-6183-4a0d-85ac-61d4221fc921
Dexilant
A dexlansoprazole product containing dexlansoprazole, registered in United States by Takeda Pharmaceuticals America, Inc.. The same ATC class is registered in 6 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Dexlansoprazole is registered in 6 of 19 countries.
Countries holding a registration under ATC A02BC06 (dexlansoprazole), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 4 of them publish a price we can compare per daily dose
Dexlansoprazole · ATC A02BC06
6 / 19 countries
- Belgiumprice
- Canada
- Germany
- Polandprice
- Switzerlandprice
- United Statesprice
Price per daily dose
What a daily dose of dexlansoprazole costs, country by country.
Normalised to the WHO defined daily dose (30 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Dexlansoprazole · price per daily dose (30 mg)
USD · FX 28 Sept 2026
- CH Switzerland$1.25
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- DEXLANSOPRAZOLE
- Manufacturer
- Takeda Pharmaceuticals America, Inc.
- Country
- United States (US)
- ATC code
- A02BC06
- ATC class
- Dexlansoprazole
- Defined daily dose
- 30 mg, O
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 14
- ndc1164764171007 CAPSULE, DELAYED RELEASE in 1 BOTTLE (64764-171-00)
- ndc1164764171015 BLISTER PACK in 1 TRAY (64764-171-01) / 4 CAPSULE, DELAYED RELEASE in 1 BLISTER PACK
- ndc1164764171031 BOTTLE in 1 CARTON (64764-171-03) / 5 CAPSULE, DELAYED RELEASE in 1 BOTTLE
- ndc11647641711110 BLISTER PACK in 1 CARTON (64764-171-11) / 10 CAPSULE, DELAYED RELEASE in 1 BLISTER PACK
- ndc1164764171191000 CAPSULE, DELAYED RELEASE in 1 BOTTLE (64764-171-19)
- ndc11647641713030 CAPSULE, DELAYED RELEASE in 1 BOTTLE (64764-171-30)
- ndc11647641719090 CAPSULE, DELAYED RELEASE in 1 BOTTLE (64764-171-90)
- ndc1164764-171-00
- ndc1164764-171-01
- ndc1164764-171-03
- ndc1164764-171-11
- ndc1164764-171-19
- ndc1164764-171-30
- ndc1164764-171-90
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
142 interactions on record for dexlansoprazole.
Graded by severity as the source publishes them — 22 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Dexlansoprazole · interactions on record
142 records
- 22 severe
- 87 moderate
- 29 minor
Most severe, free to view
- NelfinavirJ05AE04severe
- AtazanavirJ05AE08severe
- RilpivirineJ05AG05severe
- Sofosbuvir and velpatasvirJ05AP55severe
4 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Dexlansoprazole in 5 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CanadaAPO-DEXLANSOPRAZOLEAPOTEX INC
- SwitzerlandDexilant
- BelgiumDexilant 30 mgTakeda Belgium
- PolandDexilantTakeda Pharma Sp. z o.o.
- GermanyDexilantTakeda Gmbh
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Germany · Dexilant
- Lithuania · Dexilant
- Poland · Dexilant
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f04b0b2b-ca36-4fd0-a92d-c56eb9c97d01 GET /v1/drugs/f04b0b2b-ca36-4fd0-a92d-c56eb9c97d01?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": "30",
"substance": "DEXLANSOPRAZOLE",
"productndc": "64764-171",
"dosage_form": "CAPSULE, DELAYED RELEASE",
"dea_schedule": null,
"strength_unit": "mg/1",
"application_number": "NDA022287",
"marketing_category": "NDA"
}See everything about dexlansoprazole.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.